search icon
      blog search icon

      Longeveron Inc. (LGVN)’s Alzhimer’s Study-Related Rally Culminate in Corrections - Stocks Telegraph

      By Gule Rukhsar

      Published on

      April 1, 2022

      4:09 AM UTC

      Longeveron Inc. (LGVN)’s Alzhimer’s Study-Related Rally Culminate in Corrections - Stocks Telegraph

      Aging brings multiple woes to the human body, including those ailments and disorders which impact the quality of life immensely. Some are even life-threatening. A company working on therapies for such conditions is Longeveron Inc. (LGVN).

      The clinical-stage biotech company garnered tremendous interest from investors on March 31, 2022. Thus, the stock was trending at a wild 4,431% of its average volume of shares on Thursday. The stock took off and flew sky high during intraday trading to report a surge of over 105.36%. This uptick in the stock comes from the company’s publication of Alzheimer’s study data in the Alzheimer’s & Dementia® journal.

      Inevitably such a huge rise in the stock was followed by a downtrend in the after-hours session. LGVN stock fell prey to corrections in the after-hours as it shed 9.28% in the later session.

      Source: AcademiaMag

      LGVN’s Movement Analysis

      While the stock’s latest upsurge culminated in corrections, LGVN has a picture full of green. The drug makers ha been largely bullish with the stock making some nice gains throughout 2021. The bullish momentum has so far continued into the current year as well with year-to-date gains of 14.33%. The prior year’s gains stand at a monumental 112.63%.

      Given the success of its Alzheimer’s treatment candidate thus far, the company is on track for a bright future holding possible commercialization of the drug in the coming years.

      Alzheimer’s Study & Latest Publication

      The company’s Alzheimer’s disease (AD) study has been famous among the investors who have placed their bets on the company each time any related announcement was made. As per the latest news, the trial has been a success so far with the primary endpoint being achieved in the Phase 1 testing. Depicting good tolerability, the under-study drug candidate, Lomecel-B has shown promising results in mild AD patients. Hence, the data warrants further exploration of the drug’s therapeutic potential in AD.

      The promising data from the trial were published in Alzheimer’s & Dementia®: The Journal of Alzheimer’s Association.

      LGVN’s Financial Overview

      As per the latest financials, the company’s performance was not so impressive in the ending quarter of 2021. LGVN reported a decline in revenue and an increase in net loss for the fourth quarter. Therefore, the reported revenue for the quarter was $0.2 million against the comparable $1.2 million in Q4 2020. A major contributor to this decline in revenue was a row down in clinical trial and grant revenue.

      Moreover, the net loss stood at $4.1 million for the quarter with a per-share loss increasing to 2 cents.

      More From Stocks telegraph